PURPOSE: To analyze the prognostic relevance of circulating T cells responding to NY-ESO-1, Melan-A, MAGE-3, and survivin in patients with melanoma with distant metastasis. PATIENTS AND METHODS: We examined 84 patients with follow-up after analysis (cohort A), 18 long-term survivors with an extraordinarily favorable course of disease before analysis (> 24 months survival after first occurrence of distant metastases; cohort B), and 14 healthy controls. Circulating antigen-reactive T cells were characterized by intracellular cytokine staining after in vitro stimulation. RESULTS: In cohort A patients, the presence of T cells responding to peptides from NY-ESO-1, Melan-A, or MAGE-3 and the M category according to the American Joint Committee on Cancer classification were significantly associated with survival. T cells responding to NY-ESO-1 and Melan-A (hazard ratios, 0.29 and 0.18, respectively) remained independent prognostic factors in Cox regression analysis and were superior to the M category in predicting outcome. Median survival of patients possessing T cells responding to NY-ESO-1, Melan-A, or both was 21 months, compared with 6 months for all others. NY-ESO-1-responsive T cells were detected in 70% of cohort A patients surviving > 18 months and in 50% of cohort B patients. Melan-A responses were found in 42% and 47% of patients in cohorts A and B, respectively. In contrast, the proportion was only 22% for NY-ESO-1 and 23% for Melan-A in those who died within 6 months. CONCLUSION: The presence of circulating T cells responding to Melan-A or NY-ESO-1 had strong independent prognostic impact on survival in advanced melanoma. Our findings support the therapeutic relevance of Melan-A and NY-ESO-1 as targets for immunotherapy.
PURPOSE: To analyze the prognostic relevance of circulating T cells responding to NY-ESO-1, Melan-A, MAGE-3, and survivin in patients with melanoma with distant metastasis. PATIENTS AND METHODS: We examined 84 patients with follow-up after analysis (cohort A), 18 long-term survivors with an extraordinarily favorable course of disease before analysis (> 24 months survival after first occurrence of distant metastases; cohort B), and 14 healthy controls. Circulating antigen-reactive T cells were characterized by intracellular cytokine staining after in vitro stimulation. RESULTS: In cohort A patients, the presence of T cells responding to peptides from NY-ESO-1, Melan-A, or MAGE-3 and the M category according to the American Joint Committee on Cancer classification were significantly associated with survival. T cells responding to NY-ESO-1 and Melan-A (hazard ratios, 0.29 and 0.18, respectively) remained independent prognostic factors in Cox regression analysis and were superior to the M category in predicting outcome. Median survival of patients possessing T cells responding to NY-ESO-1, Melan-A, or both was 21 months, compared with 6 months for all others. NY-ESO-1-responsive T cells were detected in 70% of cohort A patients surviving > 18 months and in 50% of cohort B patients. Melan-A responses were found in 42% and 47% of patients in cohorts A and B, respectively. In contrast, the proportion was only 22% for NY-ESO-1 and 23% for Melan-A in those who died within 6 months. CONCLUSION: The presence of circulating T cells responding to Melan-A or NY-ESO-1 had strong independent prognostic impact on survival in advanced melanoma. Our findings support the therapeutic relevance of Melan-A and NY-ESO-1 as targets for immunotherapy.
Authors: Kilian Wistuba-Hamprecht; Alexander Martens; Karin Haehnel; Marnix Geukes Foppen; Jianda Yuan; Michael A Postow; Phillip Wong; Emanuela Romano; Amir Khammari; Brigitte Dreno; Mariaelena Capone; Paolo A Ascierto; Ilja Demuth; Elisabeth Steinhagen-Thiessen; Anis Larbi; Bastian Schilling; Dirk Schadendorf; Jedd D Wolchok; Christian U Blank; Graham Pawelec; Claus Garbe; Benjamin Weide Journal: Eur J Cancer Date: 2016-07-09 Impact factor: 9.162
Authors: Paolo A Ascierto; Sanjiv S Agarwala; Gennaro Ciliberto; Sandra Demaria; Reinhard Dummer; Connie P M Duong; Soldano Ferrone; Silvia C Formenti; Claus Garbe; Ruth Halaban; Samir Khleif; Jason J Luke; Lluis M Mir; Willem W Overwijk; Michael Postow; Igor Puzanov; Paul Sondel; Janis M Taube; Per Thor Straten; David F Stroncek; Jennifer A Wargo; Hassane Zarour; Magdalena Thurin Journal: J Transl Med Date: 2017-11-16 Impact factor: 5.531
Authors: Carmen S M Yong; Valerie Dardalhon; Christel Devaud; Naomi Taylor; Phillip K Darcy; Michael H Kershaw Journal: Immunol Cell Biol Date: 2016-12-22 Impact factor: 5.126
Authors: Vijaya B Joshi; Sean M Geary; Brett P Gross; Amaraporn Wongrakpanich; Lyse A Norian; Aliasger K Salem Journal: Expert Rev Vaccines Date: 2014-01 Impact factor: 5.217
Authors: Martin Scurr; Tom Pembroke; Anja Bloom; David Roberts; Amanda Thomson; Kathryn Smart; Hayley Bridgeman; Richard Adams; Alison Brewster; Robert Jones; Sarah Gwynne; Daniel Blount; Richard Harrop; Robert Hills; Awen Gallimore; Andrew Godkin Journal: Clin Cancer Res Date: 2017-08-29 Impact factor: 12.531
Authors: Benjamin Weide; Alexander Martens; Jessica C Hassel; Carola Berking; Michael A Postow; Kees Bisschop; Ester Simeone; Johanna Mangana; Bastian Schilling; Anna Maria Di Giacomo; Nicole Brenner; Katharina Kähler; Lucie Heinzerling; Ralf Gutzmer; Armin Bender; Christoffer Gebhardt; Emanuela Romano; Friedegund Meier; Peter Martus; Michele Maio; Christian Blank; Dirk Schadendorf; Reinhard Dummer; Paolo A Ascierto; Geke Hospers; Claus Garbe; Jedd D Wolchok Journal: Clin Cancer Res Date: 2016-05-16 Impact factor: 12.531